1. Home
  2. GKOS vs WAL Comparison

GKOS vs WAL Comparison

Compare GKOS & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • WAL
  • Stock Information
  • Founded
  • GKOS 1998
  • WAL 1994
  • Country
  • GKOS United States
  • WAL United States
  • Employees
  • GKOS N/A
  • WAL N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • WAL Major Banks
  • Sector
  • GKOS Health Care
  • WAL Finance
  • Exchange
  • GKOS Nasdaq
  • WAL Nasdaq
  • Market Cap
  • GKOS 8.4B
  • WAL N/A
  • IPO Year
  • GKOS 2015
  • WAL 2005
  • Fundamental
  • Price
  • GKOS $102.04
  • WAL $76.11
  • Analyst Decision
  • GKOS Strong Buy
  • WAL Strong Buy
  • Analyst Count
  • GKOS 13
  • WAL 15
  • Target Price
  • GKOS $161.54
  • WAL $98.07
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • WAL 1.1M
  • Earning Date
  • GKOS 04-30-2025
  • WAL 04-17-2025
  • Dividend Yield
  • GKOS N/A
  • WAL 2.00%
  • EPS Growth
  • GKOS N/A
  • WAL 8.41
  • EPS
  • GKOS N/A
  • WAL 7.09
  • Revenue
  • GKOS $383,481,000.00
  • WAL $3,016,200,000.00
  • Revenue This Year
  • GKOS $27.84
  • WAL $13.49
  • Revenue Next Year
  • GKOS $27.99
  • WAL $10.02
  • P/E Ratio
  • GKOS N/A
  • WAL $10.74
  • Revenue Growth
  • GKOS 21.85
  • WAL 17.96
  • 52 Week Low
  • GKOS $88.16
  • WAL $53.75
  • 52 Week High
  • GKOS $163.71
  • WAL $98.10
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.88
  • WAL 40.46
  • Support Level
  • GKOS $98.03
  • WAL $75.24
  • Resistance Level
  • GKOS $108.62
  • WAL $81.94
  • Average True Range (ATR)
  • GKOS 3.96
  • WAL 2.48
  • MACD
  • GKOS 1.87
  • WAL 0.46
  • Stochastic Oscillator
  • GKOS 47.86
  • WAL 43.73

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Share on Social Networks: